Navamedic ASA (OB: NAVA)
Health Care · Pharmaceuticals · NO
Nkr15.55
-6.33% today · -30.6% 1Y
Navamedic ASA (OB: NAVA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $40.09M and employs 38 people.
Over the last twelve months the share price has lost 30.6%, trading between 15.10 and 26.50.
Tweenvest scores Navamedic ASA across four factors: quality 54/100, value 70/100, growth 62/100. Its strongest factor is value.
NAVA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $40.09M
- Revenue (TTM)
- $57.98M
- P/E
- —
- EPS
- -1.04
- Dividend yield
- —
- Beta (5Y)
- 0.22
- 52-week high
- Nkr26.50
- 52-week low
- Nkr15.10
- Avg volume (3M)
- —
- Shares outstanding
- 23.98M
- Employees
- 38
- Next earnings
- —
About Navamedic ASA
Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.
- ISIN
- NO0010205966
- Founded
- 2002
- Listed since
- Mar 31, 2006
- Exchange
- Oslo Bors
- Currency
- NOK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.